Reuters -- Generic drugmaker Par Pharmaceutical Cos Inc (PRX.N) reported a higher quarterly profit that significantly beat analysts’ estimates, helped by new drug launches and limited competition against some of its key products.
Reuters -- Generic drugmaker Par Pharmaceutical Cos Inc (PRX.N) reported a higher quarterly profit that significantly beat analysts’ estimates, helped by new drug launches and limited competition against some of its key products.
